CoChat

Microglia-specific targeting by novel capsid-modified AAV6 vectors

Open access
Rosario, Awilda M, Cruz, Pedro E, Ceballos-Diaz, Carolina, Strickland, Michael R, Siemienski, Zoe, Pardo, Meghan, Schob, Keri-Lyn, Li, Andrew, Aslanidi, George V, Srivastava, Arun, Golde, Todd E, Chakrabarty, Paramita · 2016 · Molecular Therapy - Methods & Clinical Development
Cited by 118

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Recombinant adeno-associated viruses (rAAV) have been widely used in gene therapy applications for central nervous system diseases. Though rAAV can efficiently target neurons and astrocytes in mouse brains, microglia, the immune cells of the brain, are refractile to rAAV. To identify AAV capsids with microglia-specific transduction properties, we initially screened the most commonly used serotypes, AAV1-9 and rh10, on primary mouse microglia cultures. While these capsids were not permissive, we then tested the microglial targeting properties of a newly characterized set of modified rAAV6 capsid variants with high tropism for monocytes. Indeed, these newly characterized rAAV6 capsid variants, specially a triply mutated Y731F/Y705F/T492V form, carrying a self-complementary genome and microglia-specific promoters (F4/80 or CD68) could efficiently and selectively transduce microglia in vitro. Delivery of these constructs in mice brains resulted in microglia-specific expression of green fluorescent protein, albeit at modest levels. We further show that CD68 promoter-driven expression of the inflammatory cytokine, interleukin-6, using this capsid variant leads to increased astrogliosis in the brains of wild-type mice. Our study describes the first instance of AAV-targeted microglial gene expression leading to functional modulation of the innate immune system in mice brains. This provides the rationale for utilizing these unique capsid/promoter combinations for microglia-specific gene targeting for modeling or functional studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mtm.2016.26

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 28

  1. Lentz, 2012, Viral vectors for gene delivery to the central nervous system, Neurobiol Dis, 48, 179, 10.1016/j.nbd.2011.09.014 · DOI · Paper page
  2. Murlidharan, 2014, Biology of adeno-associated viral vectors in the central nervous system, Front Mol Neurosci, 7, 76, 10.3389/fnmol.2014.00076 · DOI · Paper page
  3. Grimm, 2015, E pluribus unum: 50 years of research, millions of viruses, and one goal-tailored acceleration of AAV evolution, Mol Ther, 23, 1819, 10.1038/mt.2015.173 · DOI · Paper page
  4. Chakrabarty, 2013, Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain, PLoS One, 8, e67680, 10.1371/journal.pone.0067680 · DOI · Paper page
  5. Ayers, 2015, Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice, Mol Ther, 23, 53, 10.1038/mt.2014.180 · DOI · Paper page
  6. Weinberg, 2013, Adeno-associated virus (AAV) gene therapy for neurological disease, Neuropharmacology, 69, 82, 10.1016/j.neuropharm.2012.03.004 · DOI · Paper page
  7. Pandya, 2014, Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy, Immunol Cell Biol, 92, 116, 10.1038/icb.2013.74 · DOI · Paper page
  8. Aslanidi, 2012, High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors, Vaccine, 30, 3908, 10.1016/j.vaccine.2012.03.079 · DOI · Paper page
  9. Zhong, 2008, Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction, Mol Ther, 16, 290, 10.1038/sj.mt.6300376 · DOI · Paper page
  10. Clarke, 1998, Myeloid-specific gene expression, J Leukoc Biol, 63, 153, 10.1002/jlb.63.2.153 · DOI
  11. Asokan, 2012, The AAV vector toolkit: poised at the clinical crossroads, Mol Ther, 20, 699, 10.1038/mt.2011.287 · DOI · Paper page
  12. Cucchiarini, 2003, Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors, Gene Ther, 10, 657, 10.1038/sj.gt.3301925 · DOI
  13. Bartlett, 1998, Selective and rapid uptake of adeno-associated virus type 2 in brain, Hum Gene Ther, 9, 1181, 10.1089/hum.1998.9.8-1181 · DOI · Paper page
  14. Pfrieger, 2012, Genetic approaches to study glial cells in the rodent brain, Glia, 60, 681, 10.1002/glia.22283 · DOI · Paper page
  15. Balcaitis, 2005, Lentiviral transduction of microglial cells, Glia, 50, 48, 10.1002/glia.20146 · DOI · Paper page
  16. Martino, 2013, Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells, Blood, 121, 2224, 10.1182/blood-2012-10-460733 · DOI · Paper page
  17. Jayandharan, 2011, Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy, Proc Natl Acad Sci USA, 108, 3743, 10.1073/pnas.1012753108 · DOI · Paper page
  18. Aslanidi, 2013, Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?, PLoS One, 8, e59142, 10.1371/journal.pone.0059142 · DOI · Paper page
  19. Martino, 2009, Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity, PLoS One, 4, e6376, 10.1371/journal.pone.0006376 · DOI · Paper page
  20. LoDuca, 2009, Hepatic gene transfer as a means of tolerance induction to transgene products, Curr Gene Ther, 9, 104, 10.2174/156652309787909490 · DOI · Paper page
  21. Horowitz, 2012, Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection, ACS Chem Biol, 7, 1059, 10.1021/cb3000265 · DOI
  22. Li, 2010, High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy, Hum Gene Ther, 21, 1527, 10.1089/hum.2010.005 · DOI · Paper page
  23. Tydlacka, 2008, Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons, J Neurosci, 28, 13285, 10.1523/JNEUROSCI.4393-08.2008 · DOI · Paper page
  24. Niwa, 1991, Efficient selection for high-expression transfectants with a novel eukaryotic vector, Gene, 108, 193, 10.1016/0378-1119(91)90434-D · DOI · Paper page
  25. Zhong, 2004, Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo, Mol Ther, 10, 950, 10.1016/j.ymthe.2004.07.018 · DOI · Paper page
  26. Chen, 2011, Cellular fusion for gene delivery to SCA1 affected Purkinje neurons, Mol Cell Neurosci, 47, 61, 10.1016/j.mcn.2011.03.003 · DOI
  27. Zolotukhin, 1999, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther, 6, 973, 10.1038/sj.gt.3300938 · DOI · Paper page
  28. Wang, 2012, Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation, Hum Gene Ther Methods, 23, 225, 10.1089/hgtb.2012.090 · DOI · Paper page

Cited by

Metadata

Authors
Rosario, A. M., Cruz, P. E., Ceballos-Diaz, C., Strickland, M. R., Siemienski, Z., Pardo, M., Schob, K.-L., Li, A., Aslanidi, G. V., Srivastava, A., Golde, T. E., & Chakrabarty, P.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2016
Volume
3
Pages
16026
ISSN
2329-0501 (ISSN-L)
OpenAlex
W2336296004
Cited by
118
References
15
FWCI
6.36
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.